Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select ...
New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn CARLSBAD, Calif., Jan. 12, 2025 (GLOBE …